FDA approves Triumeq for treatment of HIV-1

LONDON — ViiV Healthcare announced that the Food and Drug Administration has approved Triumeq (abacavir 600 mg, dolutegravir 50 mg and lamivudine 300 mg) tablets for the treatment of HIV-1 infection. Triumeq is the company's first  dolutegravir-based fixed-dose combination.



"ViiV Healthcare is committed to delivering advances in care and new treatment options to physicians and people living with HIV. We are proud to announce this important milestone, marking the second new treatment to be approved in the US from our pipeline of medicines," Dr. Dominique Limet, CEO ViiV Healthcare, said.